Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Consensus "Moderate Buy": Five brokerages give Rani Therapeutics a consensus rating of "Moderate Buy" (four buys, one sell) with an average 12‑month price target of $7.50, though individual analyst views range from a $11 target down to a sell rating.
• Quarterly miss and market position: RANI reported EPS of -$0.07 versus an expected -$0.03 and revenue of $1.46M versus $5.0M expected; the stock trades around $0.81 with a market cap near $98M, indicating high volatility and execution risk.
• Core technology: The company is a clinical‑stage biopharma developing the RaniPill oral injector for large‑molecule drugs and has demonstrated proof‑of‑concept for oral insulin delivery.

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $7.50.

A number of research firms recently commented on RANI. HC Wainwright reaffirmed a "buy" rating and issued a $11.00 target price on shares of Rani Therapeutics in a research note on Friday, March 27th. Canaccord Genuity Group cut their price objective on shares of Rani Therapeutics from $9.00 to $5.00 and set a "buy" rating for the company in a research note on Wednesday. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Rani Therapeutics in a report on Friday.

Institutional Investors Weigh In On Rani Therapeutics

A number of large investors have recently added to or reduced their stakes in RANI. Jefferies Financial Group Inc. purchased a new stake in Rani Therapeutics in the 4th quarter worth approximately $40,000. Virtu Financial LLC purchased a new position in shares of Rani Therapeutics during the fourth quarter valued at approximately $69,000. OMERS ADMINISTRATION Corp bought a new position in shares of Rani Therapeutics during the fourth quarter valued at approximately $93,000. Farallon Capital Management LLC bought a new position in shares of Rani Therapeutics during the fourth quarter valued at approximately $105,000. Finally, Bridgeway Capital Management LLC purchased a new stake in Rani Therapeutics in the fourth quarter worth $155,000. Institutional investors own 30.19% of the company's stock.

Rani Therapeutics Price Performance

NASDAQ RANI traded up $0.07 during trading on Wednesday, reaching $0.81. The company's stock had a trading volume of 2,323,990 shares, compared to its average volume of 1,171,988. The firm has a fifty day moving average of $1.25 and a 200 day moving average of $1.32. Rani Therapeutics has a one year low of $0.39 and a one year high of $3.87. The stock has a market capitalization of $97.86 million, a PE ratio of -1.37 and a beta of 0.39.

Rani Therapeutics (NASDAQ:RANI - Get Free Report) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.04). The firm had revenue of $1.46 million during the quarter, compared to analysts' expectations of $5.00 million. Research analysts expect that Rani Therapeutics will post -1.01 earnings per share for the current fiscal year.

Rani Therapeutics Company Profile

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company's proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.